SHANGHAI, Sept. 17, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the updated long-term follow-up results of Phase I clinical trial of zevorcabtagene autoleucel (zevor-cel,...
Hence then, the article about carsgen presents updated long term follow up results for zevor cel at ims 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025 )
Also on site :
- ‘River Monsters’ Star Jeremy Wade Announces Major Return Nearly 10 Years After Fan-Favorite Show Ended: ‘I’m Back’
- In 1940, Hattie McDaniel became the first African American to win an Oscar and had to sit at a segregated table; the Academy replaced her lost statuette in 2023
- Golden Goose Teams With Disney for Mickey Mouse-Inspired Sneakers, Apparel and Global Customization Tour